# Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05990452/  
OnCo record `nct05990452` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of 9MW2921 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., active and no longer recruiting.

## Summary

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05990452 by Mabwell (Shanghai) Bioscience Co., Ltd., with 261 participants enrolled, started 2023-08-28 and due to reach its primary completion in 2026-09-01. Interventions recorded: 9MW2921.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05990452
- Phase: 1/2
- Setting: A Phase I/II First-in-human Study of 9MW2921 to Evaluate the Safety, Tolerability and Preliminary Efficacy of 9MW2921 in Patients With Advanced Solid Tumors
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 261

## Sources

- ClinicalTrials.gov NCT05990452: https://clinicaltrials.gov/study/NCT05990452

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05990452.json